O-Linked β-N-acetylglucosamine (O-GlcNAc) modification: a new pathway to decode pathogenesis of diabetic retinopathy
Clin Sci (Lond) (2018) 132 (2): 185–198.
Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease
Clin Sci (Lond) (2018) 132 (2): 199–212.
Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis
Gian Luca Bagnato; Natasha Irrera; Gabriele Pizzino; Domenico Santoro; William Neal Roberts; Gianfilippo Bagnato; Giovanni Pallio; Mario Vaccaro; Francesco Squadrito; Antonino Saitta; Domenica Altavilla; Alessandra Bitto
Clin Sci (Lond) (2018) 132 (2): 231–242.
Sex-dependent differences in inflammatory responses during liver regeneration in a murine model of acute liver injury
Debora Bizzaro; Marika Crescenzi; Rosa Di Liddo; Diletta Arcidiacono; Andrea Cappon; Thomas Bertalot; Vincenzo Amodio; Alessia Tasso; Annalisa Stefani; Valentina Bertazzo; Giacomo Germani; Chiara Frasson; Giuseppe Basso; Pierpaolo Parnigotto; Malcolm Ronald Alison; Patrizia Burra; Maria Teresa Conconi; Francesco Paolo Russo
Clin Sci (Lond) (2018) 132 (2): 255–272.
Redin A. Spann; William J. Lawson; Gene L. Bidwell, III; C. Austin Zamarripa; Rodrigo O. Maranon; Sibali Bandyopadhyay; Erin R. Taylor; Jane F. Reckelhoff; Michael R. Garrett; Bernadette E. Grayson
Clin Sci (Lond) (2018) 132 (2): 295–312.
Cover ImageOleic-acid-treated HepG2 cells immunostained for PGC-1α (PPARγ co-activator-1 α). In Clinical Science volume 132, issue 1, the results of work by Bernardi et al. include reporting that the protein TRAIL (TNF-related apoptosis inducing ligand) increases the expression of PGC-1α in HepG2 cells cultured with oleic acid. Overall, the article points to a potential therapeutic role for TRAIL against impaired glucose tolerance and non-alcoholic fatty liver disease; for details see pages 69–83.